Hospice Sector: Fiscal Support and Cost of Living

Bambos Charalambous Excerpts

Thursday 2nd March 2023 Westminster Hall

[Bambos Charalambous (Enfield, Southgate) (Lab)]

It is a pleasure to serve under your chairmanship, Mr Paisley. I congratulate the hon. Member for North Ayrshire and Arran (Patricia Gibson) on securing this timely and important debate.

The work of hospices is incredible. I am lucky that North London Hospice has a facility in my constituency, as well as others in north London. The support it provides is absolutely essential, not just to people at the end of their lives, but to their family and friends. In my constituency, we have a wellbeing centre that provides therapies and counselling. We also have something called a death café, where people can talk about end of life. I was very lucky to know a constituent, Joy Watkins, who has sadly passed away now. She said that going to the death café enabled her to make choices about the end of her life. She could make choices about who to spend time with and about the finances that she would make use of at the end of her life. It transformed the way in which she handled the end of her life. The work of hospices is clearly incredible, and we need to celebrate it.

Hospices are very much part of the community. As the hon. Lady said, they rely on fundraising for much of their support. The statutory support from the clinical commissioning groups can range from 1% to 50%, and the rest of it has to be found through fundraising. Marie Curie said in its briefing that as much as 80% of hospices’ finances come from fundraising efforts such as marathon runs.

I do not know whether many people read in yesterday’s newspapers that a 13-year-old boy, Max Woosey, has raised over £700,000 for his hospice in north Devon by camping outside in a tent for three years. People make those superhuman efforts because they care so much about the services provided by hospices.

As has been the case for many charities, hospices have been hit by the cost of living crisis. People are tightening their belts because they are struggling to make ends meet, which has an impact on the amount of money raised by charities. It hits them hard because there is less money to go around, so they have to make savings. Hospices are different from most charities, however, because they have no choice about the support they provide. People are there to receive end-of-life care, and hospices have to meet their energy costs to provide that care. They also have to provide support through the specially trained hospice staff who assist people at the end of life. Clearly, hospices do not have any choice about whether they spend their money on energy bills, so they are in desperate need of support.

In my constituency, North London Hospice now faces an energy bill of more than £460,000 in 2023-24—an increase of £280,000. That is a huge amount of money, and it is more that can be bridged by any additional fundraising efforts. Although the energy bills discount scheme is welcome, it needs to be extended because, as I mentioned earlier, hospices do not have any other means of finding extra money. Fundraising is already very tight for hospices, so we need to make sure that we ask the Government for this funding. The Budget is only a couple of weeks away, and I hope that the Chancellor listens to our request.

There is also a wider argument, which I am not proposing to make today, about the funding for hospices generally. The service they provide should not just be a voluntary service that is topped up by whatever fundraising available. Hospices actually help the NHS by providing additional assistance. There should not be a postcode lottery whereby clinical commissioning groups choose to give hospices funding according to how they are prioritised in their areas. We need to look at the funding model for hospices.

Today, however, we are asking, in these very unusual and extreme circumstances, for the Chancellor to find additional money to support hospices, because it is some of our most vulnerable people who need their support. They are literally at the end of their lives, and hospices have no other way to receive funding. I urge the Minister—though it may not be up to him; it may be down to the Chancellor—to find the additional funding.

Before I close, I thank Hospice UK and Marie Curie for the excellent briefings they have provided for today’s debate. It is a shame that more Members are not present. I know that if the debate had taken place at another time, it would have been very well attended. I will leave it there, and I look forward to hearing from the Minister. I may have to leave before the end of the debate, so I apologise for that in advance, Mr Paisley.

NHS Workforce Expansion

Bambos Charalambous Excerpts

Tuesday 28th February 2023 Commons Chamber

[Wes Streeting]

I apologise for keeping my hon. Friend bobbing—the last thing the NHS needs is another patient, so I hope the exercise has been good for his joints rather than the straw that breaks that camel’s back.

My hon. Friend is absolutely right. I think cancer treatment is in many respects the canary in the coalmine, because it is an area where speed really does matter and where early detection can make a huge difference to the success of the outcomes. It is why, when we were in government, we had a cancer guarantee. By pursuing that cancer guarantee and making sure that patients received timely access to both diagnosis and treatment, the rising tide for cancer patients lifted all ships, and we saw a general improvement in the NHS, so that by the time we left government we had the lowest waiting times in history.

I am deeply anxious that within those waiting lists, which stand at a record in excess of 7 million now, will be a huge amount of undiagnosed cancer. As I know from personal experience of going to accident and emergency with something else, it is often in A&E departments that cancer is detected. I worry how many cancer patients like me will arrive at A&E, see the waiting times and walk away with a cancer undiagnosed. It certainly keeps me awake at night, and it should keep Ministers awake at night too.

[Bambos Charalambous (Enfield, Southgate) (Lab)]

I congratulate my hon. Friend on an excellent speech. Is he aware that Macmillan Cancer Support has today published research showing that 2022 was the year in which all national cancer targets were missed in at least one month? That is truly shocking, and it is why we need an NHS workforce plan urgently. Does he agree that it is about time the Government came forward and produced such a plan?

[Wes Streeting]

I wholeheartedly agree with my hon. Friend. Unless the NHS has the staff it needs, patients will not get the timely care they deserve. It really is as simple as that. We have a plan; the Government do not, and they are very welcome to take ours.

International Thalassaemia Day

Bambos Charalambous Excerpts

Wednesday 27th April 2022 Westminster Hall

[Stewart Hosie (in the Chair)]

I will call Bambos Charalambous to move the motion and then the Minister to respond. There will not be an opportunity for the Member in charge to wind up, as is the convention in 30-minute debates.

[Bambos Charalambous (Enfield, Southgate) (Lab)]

I beg to move,

That this House has considered International Thalassaemia Day 2022.

It is a pleasure to serve under your chairmanship, Mr Hosie.

International Thalassaemia Day is on 8 May, and this year’s message is “Be Aware. Share. Care.” The first part of the message is about raising awareness, so what is thalassaemia? Thalassaemias are inherited blood disorders that lower, alter or stop the production of haemoglobin in the blood. That leads to anaemia, which might be severe or life-threatening if not managed appropriately. There are several types of thalassaemia, depending on the severity of the mutation inherited. The most severe type is beta thalassaemia major, or transfusion-dependent thalassaemia, followed by beta thalassaemia intermedia and haemoglobin H disease.

Those living with transfusion-dependent thalassaemia receive blood transfusions every three weeks for life and daily iron chelation therapy. All patients develop secondary conditions and complications due to thalassaemia and iron overload. Sadly, they develop conditions such as diabetes, heart failure, osteoporosis and liver failure. Patients therefore have to spend a lot of time in hospital, whether it is for blood transfusions for thalassemia, or for the treatment and monitoring of secondary conditions.

Thalassaemia is not transmitted by transfusion, infection, environmental conditions or other factors, but is recessively inherited. It is more prevalent in individuals with Caribbean, South American, African, Mediterranean, south Asian, south-east Asian and middle eastern ancestry. Due to migration over centuries, it is found throughout the world, and it is estimated that there are 100 million people worldwide with a thalassaemia trait who are asymptomatic.

The prevalence of thalassaemia varies across different regions in the UK. Data published in 2020 by the National Haemoglobinopathy Registry—the NHR—indicates that there were more than 900 people living with beta thalassaemia major in the UK, 238 living with beta thalassaemia intermedia, 280 with beta thalassaemia/Hb E disease, and 300 with haemoglobin H disease.

The majority of patients with thalassaemia in the UK come from a British Pakistani or British Asian community. Each year, around 20 to 30 couples in the UK are identified as being at high risk of having a baby with a form of thalassaemia. My constituency of Enfield, Southgate has the highest number of people with thalassaemia in the UK and is home to the UK Thalassaemia Society, which campaigns for greater awareness and better health outcomes for people with thalassaemia. It has also given me advice and shared its findings for this debate.

The second part of the message for International Thalassaemia Day is about sharing—sharing essential information and knowledge to support the best health and social care outcomes for people with thalassaemia. The Department of Health and Social Care published its UK rare diseases framework last year, which acknowledged a number of challenges and set out the Government’s four priorities, which include increasing awareness of rare diseases among healthcare professionals, better co-ordination of care, and improving access to specialist care treatments and drugs, all of which I and the thalassaemia community very much support.

I want to focus on the last point about improving access to specialist care treatments and drugs. Thalassaemia is a rare disease and there are very few treatments for the condition. Some gene therapies have been developed, but have often not been able to progress beyond the National Institute for Health and Care Excellence’s criteria because either the formula for quality-adjusted life years is loaded against people with rare diseases or there is a smaller sample of people upon whom the gene therapy trials have been conducted. That is primarily because people with rare diseases are often few in number, and that limits who the therapy can be trialled on.

I note that NICE has done its methods and processes review, but I ask the Minister to ensure that the highly specialised technology and standard technology appraisal pathways are both fit for purpose for people with rare diseases, and that the uncertainty of cost effectiveness due to small population sizes is a serious consideration for NICE in assessing the appraisal of new gene-therapy technologies. Gene therapy and other technologies for people with rare diseases are literally a matter of life and death, and much more work needs to be done by the Government to ensure that people with rare diseases are not disadvantaged by the bureaucratic processes that fail to take into account the unique nature and impact of rare diseases on those who have to live with them.

The final part of the message is about care. This is about the experience of people with thalassaemia when receiving healthcare. I have met a number of people with thalassaemia who have shared their experiences with me. They require regular blood transfusions, and they told me about their pain and suffering following transfusions and how debilitating that can be. I have also read testimonies of people with thalassaemia who have experienced differing levels of treatment by health professionals. Because the condition tends to be extremely specific to a particular ethnic group in the UK and there are very small numbers of patients, the UKTS has found a huge disparity in services throughout the country with regard to the accessibility of thalassaemia care.

[Mr Pat McFadden (Wolverhampton South East) (Lab)]

I am grateful to my hon. Friend for the speech he is making. On care, I do not know if he has had a chance to read the report from the sickle cell and thalassaemia all-party parliamentary group entitled, “No One’s Listening”. Sickle cell is not exactly the same thing as thalassaemia. There are differences, but there are similarities too in people’s experiences. Does he share my hope that that report will serve as a turning point to win a resolve for better treatment and greater understanding of these conditions, all the way from the Department of Health and Social Care through to the decision makers in the NHS?

--- Later in debate ---

[Bambos Charalambous]

My right hon. Friend makes an excellent point. I am aware of the report and have read it. He is absolutely right that much more needs to be done to ensure that people with thalassaemia, sickle cell and other rare diseases get the treatment they need. It is also about better training for health professionals to identify the symptoms of thalassaemia, sickle cell and other such conditions, so that people with thalassaemia are not disadvantaged when they come into contact with health professionals for the first time.

According to the UK Thalassaemia Society, the experience of their members is that the UK’s thalassaemia services are under-resourced, underdeveloped and understaffed, even compared with the treatment received by those with other blood disorders. Part of the work that the UK Thalassaemia Society has been involved in over several years is to review sickle cell and thalassaemia units throughout the country and all aspects that make up the patient pathway, from emergency care to in-patient and out-patient services. There appears to be evidence of health inequalities between the treatment of patients with thalassaemia and patients with other conditions.

As we know, thalassaemia particularly impacts specific ethnic groups, such as the British Asian population in the UK, and patients have reported to the UK Thalassaemia Society that they often feel that their ethnicity is linked to below standard treatment, and they have on occasion reported distressing instances of overt racism in connection with their treatment. That has sometimes severely impacted patients’ mental health, with patients describing feeling defeated and, in the worst instances, not wanting to live any more.

The UKTS has found that patients and families in some cases are afraid to talk to the managers and nurses involved about the instances described as they are fearful that they will receive worse treatment and be stereotyped further. As a result, they have chosen to suffer in silence. That is obviously extremely concerning, and I will happily share more information about that with the Minister outside the debate. I am sure that, like me, the Minister will find it entirely unacceptable that the ethnicity of patients in any way affects treatment or, in the worst cases, leads to deeply offensive racism.

It is worth noting that thalassaemia affects many ethnicities, though predominantly those of Asian heritage, and the average life span is considerably lower in the Asian population than in the Mediterranean population. That may be for a variety of reasons; however, there is certainly worry among members of the UK Thalassaemia Society that the racial disparity they encounter may have an impact on their health outcomes. Again, I would be grateful if the Minister took that concern on board and raised it with health professionals.

I hope this debate will help raise awareness of thalassaemia and the particular difficulties that patients face. I hope the Minister will tell us how she will work to improve equal access to care and equal health outcomes for this community. How does she believe we can tackle the explicit and implicit discriminatory attitudes that still exist in healthcare settings? I thank the UK Thalassaemia Society, Genetic Alliance UK and the Royal College of Pathologists for providing me with information for the debate. I hope the Minister will take my points into consideration and re-evaluate the Government’s position on thalassaemia and rare diseases, to see what more can be done to improve health outcomes for people with thalassaemia and to raise awareness of the condition among health professionals and the wider public.

Randox Covid Contracts

Bambos Charalambous Excerpts

Wednesday 17th November 2021 Commons Chamber

[Angela Rayner]

My hon. Friend makes an important point. We have heard about this distinction from other companies and organisations that have experience in the field; they feel as though they were blocked and there was not a transparent process for them to go through. We have seen concerns about how procurement decisions were being made for companies such as Randox, with the lack of any paper trail showing that they were made properly. How is that fair? The question is very simple: what are Ministers hiding?

[Bambos Charalambous (Enfield, Southgate) (Lab)]

Is that not the nub of the point: the fact that Ministers are using WhatsApp messages to make contracts is a way of circumventing the procurement process, which is there to protect the probity of Government spending? That is why we should be challenging these things as firmly as we can.

[Angela Rayner]

My hon. Friend makes a good point on probity. If Ministers have nothing to hide and no rules were broken, surely they would be happy to publish the details of these meetings and the correspondence. But they have refused time and time again to do so. So today we have tabled this motion and we will put it to a vote, because the only logical conclusion is that there is something to hide—that the dodgy lobbying at the heart of this scandal has played a part in how vast sums of taxpayers’ cash have been spent.

Covid-19 Update

Bambos Charalambous Excerpts

Monday 19th April 2021 Commons Chamber

[Matt Hancock]

My hon. Friend raises an important point, and I am happy to look into it. I am also pleased that the cost of the tests that are needed for travel is coming down, and an important piece of work is under way to see how we can get that down further. Nevertheless, my hon. Friend makes a strong case for her constituent.

[Bambos Charalambous (Enfield, Southgate) (Lab)]

Face coverings are likely to remain a feature to protect against covid-19, but people with hidden disabilities who cannot wear such coverings will face abuse. Despite raising the matter on previous occasions, including once with the Prime Minister, and having been promised an awareness campaign, nothing has happened. Will the Secretary of State tell me when that campaign will happen?

[Matt Hancock]

Yes, an awareness campaign is under way, and I am grateful for advance notice of this question. I will write to the hon. Gentleman with the full details. He may say to me, “Sorry, Matt; more needs to be done,” in which case I will look into it, but he makes an important point on which I essentially agree with him.

UK Rare Diseases Framework

Bambos Charalambous Excerpts

Wednesday 24th March 2021 Westminster Hall

[Bambos Charalambous (Enfield, Southgate) (Lab)]

It is a pleasure to serve under your chairmanship, Mrs Miller. I congratulate my hon. Friend the Member for Blaydon (Liz Twist) on securing this important debate and on her excellent opening speech.

As chair of the all-party parliamentary group on sickle cell and thalassaemia, I know that this subject is of great interest to people with thalassaemia. I will focus my speech on one of the four high-level priorities of the framework: improved access to specialist care, treatment and medicine. People with rare diseases say that the tantalising prospect that one day there will be a cure for the rare diseases affecting them is something that gives them hope and huge motivation, and that drives them to campaign passionately for the development, and then approval, of that medicine or therapy. When it comes to assessing the effectiveness of such drugs or treatments for rare diseases, however, the approach taken by NICE leaves a lot to be desired.

Recently, NICE gave a provisional negative appraisal to a ground-breaking gene therapy treatment that would have eliminated the need for the chronic treatment of many people with a severe form of thalassaemia. One of the contentious issues with NICE’s assessment has been the inflexibility of the arbitrary discount rates. The small number of people with rare diseases means that there is often insufficient evidence available to satisfy NICE’s assessors. I note that NICE has undertaken a methods review process in which the discount rate is a key area of potential reform, which I very much welcome. Additionally, I want to ask NICE to take greater account of the testimony from patients, because only by understanding patients’ lived experience can a committee properly assess the effectiveness of a drug or treatment.

For people with rare diseases such as thalassaemia, the approval of a drug or treatment can be the difference between life and death. It is imperative that we get this right, and that means things have to change quickly. We need the implementation of an action plan for the rare diseases framework, and we need it now.

Oral Answers to Questions

Bambos Charalambous Excerpts

Tuesday 23rd February 2021 Commons Chamber

[Helen Whately]

I thank my hon. Friend for his question. I can tell him that the National Institute for Health and Care Excellence published a guideline on vitamin D for covid in December. Its expert panel supported current Government advice to take vitamin D supplements through the autumn and winter. However, there is insufficient evidence that taking vitamin D mitigates effects of covid-19. I can also say that hydroxychloroquine is not recommended or authorised for the treatment of covid outside of trials.

[Bambos Charalambous (Enfield, Southgate) (Lab)]

What recent assessment he has made of the effect of the covid-19 outbreak on cancer care and treatment.

[Mick Whitley (Birkenhead) (Lab)]

What recent assessment he has made of the effect of the covid-19 outbreak on cancer care and treatment.

[The Parliamentary Under-Secretary of State for Health and Social Care (Jo Churchill)]

The tremendous efforts of our NHS cancer workforce are helping to ensure that those who need treatment can continue to access it without delay. The NHS has been clear, as have Ministers, since the beginning of the pandemic that continuation of urgent cancer care must be a priority. The NHS has established covid-secure cancer hubs, consolidated surgery, centralised triage to prioritise patients based on clinical need, and utilised the independent sector for capacity.

[Bambos Charalambous]

Staff at North Middlesex University Hospital have done an incredible job under difficult circumstances, delivering cancer care and treatment, but despite that the Government have acknowledged that more than 30,000 people are missing a diagnosis of cancer compared with 2019. With the cancer recovery plan due to expire at the end of March, can the Minister please set out her commitments to beat the backlog after March? How will a renewed cancer recovery plan help meet the ambitions for cancer care set out in the NHS long-term plan?

[Jo Churchill]

I am concerned, like the hon. Gentleman, about those who have not come forward and those who are not currently accessing treatment. I reassure him that once people do come forward, there is a speedy path to treatment. The numbers of those who are entering treatment, both on two weeks and on 31 days, is ahead of what it was at this time last year, and we are seeing enormous efforts from the cancer workforce. I am meeting this afternoon with the all-party parliamentary groups on radiotherapy and on cancer, and we will be discussing the recovery plan, which he is right goes to March. However, every single trust has been given a target to produce a plan for ongoing assessment of how it is addressing the backlog going forward.

Covid-19

Bambos Charalambous Excerpts

Monday 22nd February 2021 Commons Chamber

[Edward Argar]

My hon. Friend was a distinguished Minister in the Department for some time and rightly highlights the situation that we faced at the height of the first wave of the pandemic. It is testament to the phenomenal efforts to procure PPE of the officials in my Department, in the Paymaster General’s Department and others that we did not run out of PPE in this country. Indeed, credit for that should also go to my right hon. Friend the Secretary of State for Health and Social Care, who ensured that throughout he put the provision of PPE and people first, even when, as we have seen, that may have led to challenges and to process not being entirely adhered to in respect of the timings for the publication of contract details. He and I have the greatest respect not only for the recent judgment, which we will consider carefully, but for the importance of transparency. I believe that my right hon. Friend did the right thing: he did everything he could to ensure that his No. 1 priority was to get that PPE procured and to the frontline to protect those who were protecting all of us and helping to save lives.

As on so many occasions over the past year, in recent weeks the British people have once again made huge sacrifices to comply with the necessary restrictions. It has been incredibly hard for individuals and businesses up and down the country, but in the figures that I have set out, we can see the impact that those sacrifices have made in helping to suppress the spread of this virus.

Despite the progress, over the past week an average of 449 people still lost their lives each day—449 families and friends who have lost loved ones. It is still far, far too many. It reminds us that, even now, as we map a brighter course forward, we must never lose sight of the threat posed by this virus.

[Bambos Charalambous (Enfield, Southgate) (Lab)]

When I asked the Prime Minister a question about his road map a short while ago, he said that he supported a public awareness campaigns for people who cannot wear face coverings but are subject to abuse because people are not aware of their exemption. Does the Minister support such a campaign and will he make the same commitment as the Prime Minister, so that people do not face abuse, and so that people are educated and know that there are reasons why people cannot wear face coverings?

[Edward Argar]

The hon. Gentleman makes a typically measured and sensible point. He is absolutely right: those who are exempt from wearing face coverings for medical reasons should be able to go about their lives without fear of abuse or verbal or other attacks on them for not doing so. I heard what the Prime Minister said and I echo those words. The Paymaster General and I will look carefully at what the hon. Gentleman has just suggested in respect of what we can do as a Government to raise awareness of the fact that there are people who, for entirely legitimate reasons, are not wearing face coverings.

Finally, I turn to the third factor that has changed the situation for the better. That, of course, is our vaccine roll-out, which throughout has been key to the future. As of today, we have provided a first dose to over 17.5 million people. That is almost one in three adults in the United Kingdom. Vaccine take-up has surpassed our expectations. In England, for example, we have now given a first dose to 93% of the over-80s, to 96% of those aged between 70 and 79, and to 94% of eligible care home residents. Those are phenomenal achievements—the result of a huge team effort. In that context, I pay tribute to our NHS, to pharmacists, to the armed forces and, of course, to the army of volunteers who have done their bit to help make this process run as smoothly as it has.

Those are vital achievements because we know that vaccines save lives. The cohorts we are currently working to vaccinate by mid-April represent some 99% of covid deaths, but we will not rest until we can offer that protection to everyone. We urge, and I would urge, everyone who has been offered the vaccine to take up that offer, as I will certainly be doing when I become eligible to receive it. It is safe and it is saving lives.

With an average of 358,341 doses being given each and every day in the UK and more vaccines coming on stream in the spring, I believe that we can confidently begin to look to the future. That is why a few moments ago, at this Dispatch Box, the Prime Minister set out his road map for how we will carefully but irreversibly unlock our country. As he set out, it is based on four tests: first, that the vaccine deployment programme continues successfully; secondly, that evidence shows that vaccines are sufficiently effective in reducing hospitalisations and deaths; thirdly, that infection rates do not pose a risk of a surge in hospitalisations that would put unsustainable pressure on the NHS; and fourthly, that our assessment of the risks is not fundamentally changed by new variants of the virus that cause concern.

Our road map out of lockdown will be taken, as my right hon. Friend set out, in four steps, each step reflecting the reality on the ground, not just our understandable expectations and desires. At every stage, our decisions will be led by data, not dates, with at least five weeks between steps; we will review the data every four weeks and give one week’s notice of any changes. The dates that my right hon. Friend set out today are not target dates; they are, importantly, “no earlier than” dates. We will continue to undertake statutory reviews, including the one taking place today. Yet in doing so, we are ever mindful of those expectations and desires.

Covid-19 Update

Bambos Charalambous Excerpts

Thursday 15th October 2020 Commons Chamber

[Matt Hancock]

My hon. Friend is right to raise these issues, and these are difficult choices that we face. She has raised with me previously the need for a plan for exit so that we can motivate people to do what is needed to get the disease under control in London. In her constituency, almost more than any other, decisions to restrict social life have a significant direct impact. On economic and health grounds, getting this virus under control helps on both counts, particularly if we take into account, for instance, the mental health impacts. Having spoken to the Royal College of Psychiatrists, it is clear that the mental health impacts if the virus gets out of control are worse than the mental health impacts of the measures necessary to keep it in control, but nevertheless we have to ensure that the services are there to support people.

[Bambos Charalambous (Enfield, Southgate) (Lab)]

I wrote to the Secretary of State on 16 September about the inadequacies of track and trace, and I acknowledge what he has said today about the need for local and national teamwork, but I need to be further reassured that he will get track and trace right, because that is central to dealing with the covid-19 pandemic. London is now in tier 2, and we have seen Manchester go from tier 2 to tier 3. We need to have a national circuit break for that to work, because otherwise we will have tier 2 going piecemeal to tier 3, and that is not a plan.

[Matt Hancock]

First, yes, we want to work more closely with Ealing to make sure we get that national and local link-up in the test and trace system—I can give the hon. Gentleman that assurance. [Interruption.] And in Enfield as well. Just to be clear, no decisions have yet been taken on Greater Manchester, and I want to reassure colleagues from Greater Manchester who are in the Chamber of that. Finally, having this targeted approach is clear for people to understand. There are three levels. Everyone knows what is in each of the three levels, and it is very easy for someone to know which level their area is in.

Covid-19 Update

Bambos Charalambous Excerpts

Thursday 17th September 2020 Commons Chamber

[Matt Hancock]

Yes, of course. My hon. Friend makes the point well. We are putting more localised testing in and making sure that it is as accessible as possible. Of course, the challenge is to ensure that those tests get to the right people, prioritised appropriately, and I look forward to working with my hon. Friend to deliver that across Kent.

[Bambos Charalambous (Enfield, Southgate) (Lab)]

At least six care homes in my borough of Enfield have seen the return of covid-19 cases. At the same time, they are experiencing delays in receiving pillar 1 and pillar 2 test kits, and results are taking more than a week to arrive, potentially leading to a rise in the spread of the virus. What steps is the Minister taking to ensure that testing is not taking as long? What does he intend to do to fix this mess?

[Matt Hancock]

Making sure that test kits get returned rapidly is incredibly important, including in social care. I am glad to say that the backlog has come down over the past week. At its core, our response to the problems in social care, because so many people who live in care homes are older and therefore vulnerable, is to protect the amount of test kits. The weekly testing of staff and the monthly testing of residents has been delivered and is being protected, even despite all the other pressures on testing capacity.